Kapil Dhingra News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ludhiana: A Basant Avenue resident has lost Rs 25.

-  Appointment of Elisabeth Leiderman, M.D. -  Resignation of Kapil Dhingra, M.D. LONDON, Dec. 22, 2023 -- Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing...

Item 5.07 Submission of Matters to a Vote of Security Holders. On September 7, 2022, Replimune Group, Inc. held its annual meeting of stockholders to consider and vote on the two... | September 8, 2022

03.03.2022 - Medicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin and next generation IL-2 Dr. Dhingra has a track record of development and approval of cancer therapies and ... Seite 1

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 Clinical development plans on schedule in both hematological and solid tumor programs Leadership strengthened through key management and board appointments UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in gamma-delta bispecific T cell engagers ...